Drug General Information (ID: DDII7ZMA80)
Drug Name			Abciximab		Drug Info		Dextran (low molecular weight)		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Anticoagulants				Plasma Expanders

Mechanism of Abciximab-Dextran (low molecular weight) Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Abciximab				Dextran (low molecular weight)
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Anticoagulant effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Abciximab and Dextran (low molecular weight)

Recommended Action
Management		The use of dextran before percutaneous coronary intervention (PCI) or intent to use it during PCI is considered contraindicated by the manufacturer of abciximab.

References
1	Product Information. ReoPro (abciximab). Lilly, Eli and Company, Indianapolis, IN.